Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis

被引：0
|
作者：
Orbai, Ana-Maria [1 ]
Gladman, Dafna D. [2 ]
Birt, Julie [3 ]
Gellett, Amanda M. [3 ]
Lin, Chen-Yen [3 ]
Kvien, Tore [4 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Diakonhjemmet Hosp, Oslo, Norway
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2561
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
    Orbai, A-M
    Gladman, D. D.
    Goto, H.
    Birt, J. A.
    Gellett, A. M.
    Lin, C-Y
    Kvien, T. K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 329 - 336
  • [2] Rapid and sustained improvements in patient-reported outcomes with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
    Hasan, Tahir
    Haschemi, Nassab Mani
    Andrew, Bradley
    Georg, Pum
    Katrien, Van Beneden
    SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [3] RAPID AND SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH IXEKIZUMAB IN BIOLOGIC-NAIVE AND TNF-INADEQUATE RESPONDER PATIENTS WITH PSORIATIC ARTHRITIS
    Tahir, Hasan
    Nassab, Mani Haschemi
    Bradley, Andrew
    Pum, Georg
    Van Beneden, Katrien
    RHEUMATOLOGY, 2019, 58
  • [4] Rapid and sustained improvements in cutaneous and musculo-skeletal signs and symptoms with 108 weeks treatment of ixekizumab in psoriatic arthritis in biologic-naive and TNF-inadequate responder patients
    Gottlieb, Alice B.
    Merola, Joseph F.
    Shrom, David
    Sprabery, Aubrey T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB262 - AB262
  • [5] Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naive to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
    Sunkureddi, Prashanth
    Zhu, Baojin
    Ogdie, Alexis
    Spraberry, Aubrey
    Lisse, Jeffrey
    Lin, Chen-Yen
    Shrom, David
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [6] IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAIVE PATIENTS
    Coates, Laura C.
    Ogdie, Alexis
    Sunkureddi, Prashanth
    Kerr, Lisa
    Hufford, Matthew
    Helliwell, Philip
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 902 - 903
  • [7] Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept
    Mease, P
    Gottlieb, A
    Woolley, JM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [8] Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naive Patients with Psoriatic Arthritis
    Husni, M. Elaine
    Gowin, Kristin
    Gellett, Amanda
    Sprabery, Aubrey Trevelin
    Helt, Cameron
    Geneus, Vladimir
    Rossini, Maurizio
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [9] Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naive or with previous inadequate response to tumour necrosis factor inhibitor therapy
    Jadon, D. R.
    Nassab, M. H.
    Van Beneden, K.
    Pum, G.
    Bradley, A.
    SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [10] SUSTAINED IMPROVEMENTS IN DISEASE ACTIVITY FOR UP TO TWO-YEARS WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE EITHER BIOLOGIC-NAIVE OR WITH PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR THERAPY
    Jadon, Deepak R.
    Nassab, Mani Haschemi
    Van Beneden, Katrien
    Pum, Georg
    Bradley, Andrew J.
    RHEUMATOLOGY, 2019, 58
12345